Cargando…

Antibody fragments functionalized with non-canonical amino acids preserving structure and functionality - A door opener for new biological and therapeutic applications

Functionalization of proteins by incorporating reactive non-canonical amino acids (ncAAs) has been widely applied for numerous biological and therapeutic applications. The requirement not to lose the intrinsic properties of these proteins is often underestimated and not considered. Main purpose of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanaee-Ahvaz, Hana, Cserjan-Puschmann, Monika, Mayer, Florian, Tauer, Christopher, Albrecht, Bernd, Furtmüller, Paul G., Wiltschi, Birgit, Hahn, Rainer, Striedner, Gerald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686840/
https://www.ncbi.nlm.nih.gov/pubmed/38046162
http://dx.doi.org/10.1016/j.heliyon.2023.e22463
Descripción
Sumario:Functionalization of proteins by incorporating reactive non-canonical amino acids (ncAAs) has been widely applied for numerous biological and therapeutic applications. The requirement not to lose the intrinsic properties of these proteins is often underestimated and not considered. Main purpose of this study was to answer the question whether functionalization via residue-specific incorporation of the ncAA N(6)-[(2-Azidoethoxy) carbonyl]-l-lysine (Azk) influences the properties of the anti-tumor-necrosis-factor-α-Fab (FTN2). Therefore, FTN2(Azk) variants with different Azk incorporation sites were designed and amber codon suppression was used for production. The functionalized FTN2(Azk) variants were efficiently produced in fed-batch like μ-bioreactor cultivations in the periplasm of E. coli displaying correct structure and antigen binding affinities comparable to those of wild-type FTN2. Our FTN2(Azk) variants with reactive handles for diverse conjugates enable tracking of recombinant protein in the production cell, pharmacological studies and translation into new pharmaceutical applications.